发明名称 |
Methods of administering anti-TNFα antibodies |
摘要 |
Methods of treating disorders in which TNFα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention. |
申请公布号 |
US8974790(B2) |
申请公布日期 |
2015.03.10 |
申请号 |
US201414292707 |
申请日期 |
2014.05.30 |
申请人 |
AbbVie Biotechnology Ltd. |
发明人 |
Fischkoff Steven A.;Kempeni Joachim;Weiss Roberta |
分类号 |
A61K39/395;A61K9/00;C07K16/24;A61K39/00 |
主分类号 |
A61K39/395 |
代理机构 |
Dechert LLP |
代理人 |
Dechert LLP |
主权项 |
1. A method for treating ulcerative colitis in a human subject, comprising administering subcutaneously to a human subject having ulcerative colitis a total body dose of 40 mg of a human anti-TNFα antibody once every 13-15 days for a time period sufficient to treat the ulcerative colitis, wherein the anti-TNFα antibody comprises an IgG1 heavy chain constant region; a variable light (“VL”) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:7, a CDR2 having the amino acid sequence of SEQ ID NO:5, and a CDR3 having the amino acid sequence of SEQ ID NO:3; and a variable heavy (“VH”) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:8, a CDR2 having the amino acid sequence of SEQ ID NO:6and a CDR3 having the amino acid sequence of SEQ ID NO:4. |
地址 |
Hamilton BM |